Images List Premium Download Classic

Angioedema

Angioedema-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Enzyme formulation for reducing histamine intolerance
September 28, 2017 - N°20170274056

Disclosed is a formulation of the following enzymes: alpha-galactosidase, alpha amylase, beta glucanase, lactase, biocor dpp=iv (proprietary blend) and pectinase, which has been found to be effective in treating histamine intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: inflammation, pruritus, urticaria, hypotension, tachycardia, fatigue, migraines, conjunctivitis, incontinence, ...
Compositions and uses of amidine derivatives
Biocryst Pharmaceuticals, Inc.
September 21, 2017 - N°20170266172

Use of a compound of formula (i): wherein a, x, y, r1 and r2 as defined herein, in treating hereditary angioedema is disclosed. A composition containing the compounds, a polar organic solvent or a mixture thereof; and optionally a co-solvent, is also disclosed.
Therapeutic inhibitory compounds
Lifesci Pharmaceuticals, Inc.
September 14, 2017 - N°20170260163

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
Angioedema Patent Pack
Download + patent application PDFs
Angioedema Patent Applications
Download + Angioedema-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Angioedema-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical composition for preventing or treating angioedema, containing extract of peony root or mixture of ...
Korea Institute Of Oriental Medicine
July 27, 2017 - N°20170209510

The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which ...
Pharmaceutical composition for preventing or treating diabetic complications and angioedema, containing natural mixture extract as ...
Korea Institute Of Oriental Medicine
June 29, 2017 - N°20170182107

The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, ...
Composition of allergen extracts having reduced toxicity and method of production thereof
Stallergenes
June 08, 2017 - N°20170157240

The present invention concerns pollen allergen extracts, in particular ragweed (ambrosia) pollen allergen extracts, containing reduced amounts of copper-binding-like proteins in order to minimize the risk of toxicity, including induction of angioedema, of those allergen extracts. The invention also relates to methods of preparing pollen allergen extracts containing reduced amounts of copper-binding-like proteins.
Angioedema Patent Pack
Download + patent application PDFs
Angioedema Patent Applications
Download + Angioedema-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Angioedema-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Therapeutic inhibitory compounds
Lifesci Pharmaceuticals, Inc.
February 02, 2017 - N°20170029406

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
Dyax Corp.
January 05, 2017 - N°20170002094

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
Treatment of hereditary angioedema with c1 inhibitor
Santarus, Inc.
December 15, 2016 - N°20160361394

A method for treating acute attacks of hereditary angioedema (hae) whereby a first does and a second dose of a recombinant c1 esterase inhibitor is administered intravenously to the patient, each dose at 50 iu/kg body weight of the patient and wherein the first and second doses are administered within a 24 hour period. The recombinant c1 esterase inhibitor has an ...
Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema
Cornell University
December 01, 2016 - N°20160347822

This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human c1 esterase inhibitor or factor xii. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema.
Compositions and methods for inhibiting gene expression of factor xii
Arrowhead Madison Inc.
September 22, 2016 - N°20160272978

Rna interference (rnai) triggers for inhibiting the expression of factor xii (f12) gene through the mechanism of rna interference are described. Pharmaceutical compositions comprising one or more f12 rnai triggers together with one or more excipients capable of delivering the rnai trigger(s) to a liver cell in vivo are also described. Delivery of the f12 rnai trigger(s) to ...
Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema
Arrowhead Madison Inc.
September 22, 2016 - N°20160271112

Methods for treating or relieving at least one symptom of urticarial disorders including chronic idiopathic urticaria, angioedema, and anaphylaxis, or a combination of these disorders in a mammal, including humans. The method comprises administering to the mammal a therapeutically effective amount of pramipexole, dexpramipexole or pharmaceutically acceptable salts thereof.
Therapeutic inhibitory compounds
Lifesci Pharmaceuticals, Inc.
July 14, 2016 - N°20160200704

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
Angioedema Patent Pack
Download + patent application PDFs
Angioedema Patent Applications
Download + Angioedema-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Angioedema-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Evaluation and treatment of bradykinin-mediated disorders
Dyax Corp.
December 17, 2015 - N°20150362493

The present disclosure provides methods of evaluating a subject, e. G., a subject at risk for or suffering from a pkal-mediated or bradykinin-mediated disorder, based on values (e. G., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (kma), or other diseases mediated by pkal useful ...
Evaluation, assays and treatment of pkal-mediated disorders
Dyax Corp.
December 17, 2015 - N°20150362492

The invention provides assay methods of detecting plasma protease ci inhibitor (c1-inh) that binds plasma kallikrein, factor xii, or both, and uses thereof for identifying subjects at risk for or suffering from a pkal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (kma), or other diseases mediated by pkal useful in the evaluation and ...
Pharmaceutical composition and functional food comprising natural extracts for preventing or treating diabetic complications or ...
Korea Institute Of Oriental Medicine
December 03, 2015 - N°20150343005

The present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema containing a mixed extract of hedera helix leaves and coptis chinensis as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration ...
(aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use
Bayer Pharma Aktiengesellschaft
May 07, 2015 - N°20150126449

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein ...
Methods for modulating factor 12 expression
Bayer Pharma Aktiengesellschaft
August 14, 2014 - N°20140228300

Disclosed herein are methods for decreasing factor 12 and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to factor 12 include hereditary angioedema (hae). Methods for inhibiting factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for developing an ...
Methods for modulating kallikrein (klkb1) expression
Bayer Pharma Aktiengesellschaft
July 31, 2014 - N°20140213631

Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (hae). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an ...
Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, ...
Bayer Pharma Aktiengesellschaft
July 31, 2014 - N°20140213505

Provided herein are peptide inhibitors of the interaction between end binding protein 3 (eb3) and inositol 1,4,5-trisphosphate receptor type 3 (ip3r3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.
Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, ...
Bayer Pharma Aktiengesellschaft
June 05, 2014 - N°20140155314

Provided herein are peptide inhibitors of the interaction between end binding protein 3 (eb3) and inositol 1,4,5-trisphosphate receptor type 3 (ip3r3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.
Loading